TX-BLUE-YONDER
1.8.2024 17:13:29 CEST | Business Wire | Press release
Blue Yonder, the leader in digital supply chain transformations, today announced the closing of its acquisition of One Network Enterprises (One Network) at an enterprise value of approximately $839 million. The acquisition gives Blue Yonder customers the ability to collaborate and share data – from inventory levels to raw and finished goods materials movement – in real time across all trading partners up and down the supply chain.
With increasing volatility and continuous disruptions, retailers, manufacturers and logistics service providers (LSPs) need to achieve multi-enterprise transparency with trading partners, unify plans and actions, and conduct business in real time in order to enable more accurate cross-functional decision-making and eliminate the time gap between order planning and fulfillment. It’s no longer sufficient for companies to rely on periodic updates about their inventory, capacity, and resources; true business agility requires real-time information across an entire network.
With the addition of One Network’s commercial technology, Blue Yonder can now offer customers a multi-enterprise, multi-tier network ecosystem; artificial intelligence (AI)-powered supply chain assistants to identify, monitor, analyze, and resolve problems; and a simplified process to onboard and work with trading partners. Real-time inventory and capacity views help customers match supply and demand, detect and resolve problems, and orchestrate resources across their network of trading partners. One Network will continue to independently service and provide tailored technology solutions to its government customers.
“One Network’s industry-leading commercial technology will seamlessly be integrated into the Blue Yonder Platform. Their supply chain network and intelligent control tower deliver superpowered insights to businesses looking to fortify their supply chains,” said Duncan Angove, CEO, Blue Yonder. “Our customers can boost visibility, agility and speed thanks to a single source of truth provided by the Blue Yonder Platform and the digital network, all enhanced by our AI assistants, solvers and predictions. This allows customers to see issues both downstream and upstream in real time, so they can avoid disruptions and make better decisions. From One Network’s capabilities to its forward-looking mission, the company perfectly embodies Blue Yonder’s vision to transform the supply chain.”
With this acquisition, Blue Yonder customers will be able to address volatility and disruptions in the market, plan with greater accuracy, meet rising customer expectations, and simplify complexity within their supply chains. Blue Yonder customers will have access to the following benefits:
- Navigating increasing uncertainty and volatility with real-time visibility across multiple tiers to anticipate risks, assess scenarios, and instantly redirect resources where needed most to deliver the greatest impacts to their business and sustainability goals.
- Optimizing of resources, from capacity and inventory to workforce and carriers to better serve their business customers, capitalize on new market opportunities, and accelerate revenue growth.
- Collaborating and orchestrating of their supply chain in real-time across a global network of 150,000 (and counting) trading partners using a shared view and dataset that ensures planning objectives flow into execution and vice versa to optimize critical KPIs.
“Blue Yonder is building the supply chain of the future,” said Angove. “To succeed in today’s business environment, planning and logistics teams need to make decisions faster. They need to collaborate with more partners. They need faster responsiveness to disruptions. One Network’s multi-tier and multi-enterprise network has a large role to play here, and we’re proud to join forces with them to make a lasting difference.”
This acquisition also catalyzed Blue Yonder’s expanded presence in Dallas, where it has been hiring extensively to support its momentum. Blue Yonder is now designating Dallas as its Global Innovation Center. In May during its annual customer conference, ICON, Blue Yonder announced a new AI Innovation Studio in Dallas where the company is hosting design-led AI Agent workshops with customers. Blue Yonder also plans to add a state-of-the-art Customer Experience Center in Dallas where the company will showcase its latest innovations that are transforming complex global supply chains.
One Network is the third company Blue Yonder has acquired since Q4 2023, following Doddle in November 2023 and flexis AG in February. These deals mark approximately $1 billion in M&A investments and are emblematic of Blue Yonder’s intent to transform the global supply chain.
About Blue Yonder
Blue Yonder is the world leader in digital supply chain transformation. Global retailers, manufacturers and logistics providers leverage Blue Yonder to optimize their supply chains from planning through fulfillment, delivery and returns. Blue Yonder’s AI-embedded, interoperable supply chain solutions are connected end-to-end via a unified platform and data cloud, enabling business to collaborate in real time across functions, which supports more agile decision-making, improved customer satisfaction, profitable growth, and more resilient, sustainable supply chains. Blue Yonder - Fulfill your PotentialTM www.blueyonder.com
“Blue Yonder” is a trademark or registered trademark of Blue Yonder Group, Inc. Any trade, product or service name referenced in this document using the name “Blue Yonder” is a trademark and/or property of Blue Yonder Group, Inc. All other company and product names may be trademarks, registered trademarks or service marks of the companies with which they are associated.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240731317929/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
